NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2025 RESULTS
Menu

Back to Press Releases

NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2025 RESULTS

  • Fourth quarter total revenue of $22.1 million, up 17% year-over-year
  • Positive cash flows, with Adjusted EBITDA(1) of $1.0 million, up 9% year-over-year, and our 28th consecutive quarter of positive Adjusted EBITDA
  • Investor webinar scheduled for Thursday, March 26, 2026 at 10:00 AM ET / 7:00 AM PT

TORONTO, ONTARIO, March 26, 2026 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”) operates one of Canada’s largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain medical services markets, today announced its financial and operating results for the three months and year ended December 31, 2025, the grant of stock options (“Options”) and restricted share units (“RSUs”) and information regarding the Company’s investor webinar on Thursday, March 26, 2026. All figures are in Canadian dollars, unless otherwise noted.

“The team delivered another successful year, generating strong operating results in 2025 by serving more patients and introducing new services for Canadian patients,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “We entered 2026 in a very strong position, and I look forward to Stephen and the entire NeuPath team executing on our growth strategy.”

“I want to thank Joe and our NeuPath team for building a strong foundation that will support our future growth,” said Stephen Lemieux, NeuPath’s President and incoming Chief Executive Officer. “We expect to deliver continued growth and margin improvement in 2026, as we serve more patients, expand to new locations, and broaden the availability of innovative procedures such as Arthrosamid®.”

Financial and Operational Highlights

  • Total revenue was $22.1 million and $87.2 million for the three months and year ended December 31, 2025, up 17% versus the fourth quarter of 2024 and 20% for the year, delivering another record year of revenues;
  • Adjusted EBITDA was $1.0 million and $6.0 million for the three months and year ended December 31, 2025, up 9% over the prior year fourth quarter and 56% year-over-year; and
  • As at December 31, 2025, the Company had $4.5 million in cash and cash equivalents and interest-bearing long-term debt of $6.2 million.

(1) IFRS Accounting Standards (“IFRS”) and Other Financial Measures defined by the Company below.

View entire press release – PDF

Related Articles